The Natural History of Familial Dysautonomia

Natural History of Familial Dysautonomia

The study will collect clinical information from patients with FD and allow them to give blood to help develop biological markers of the disease to aid diagnosis and treatment.

This is a non-invasive, non-interventional, observation study that poses only minimal risk for participants. The study will document the clinical features of patients with FD overtime by storing their routine clinical test results in a central database. The study will involve collaborators at other specialist clinics around the world who follow/evaluate patients with FD annually. Providing blood for future use is optional.

Study Overview

• Status: Recruiting
• Conditions: Hereditary Sensory and Autonomic Neuropathies; Familial Dysautonomia (Riley-Day Syndrome); Hereditary Sensory and Autonomic Neuropathy 3

Detailed Description

Define the phenotypic characteristics, severity and clinical evolution of FD on a patient-by patient basis. Investigators will enroll patients with FD in a multi-center observational natural history study to evaluate their biochemical, neurological and autonomic phenotype. Investigators will follow patients to systematically study the onset and scaled severity of all clinical problems. Investigators will define progression rates of patients outside of a clinical trial to distinguish between static and progressive features, a challenge in congenital neuropathies. Investigators will continue banking blood to look for ways to monitor the disease phenotypes. Biomarkers that quantify renal, cardiovascular, respiratory, skeletal and cognitive aspects of the disease will be evaluated. This information is relevant when monitoring toxicity to drugs in clinical trials. Detailed clinical follow-up of patients with FD will allow investigators to determine when standard of care therapies (e.g., non-invasive ventilation, gastrostomy feedings) should be initiated and how these impact survival outcomes.

Specific Aim 2: Develop ways to measure progressive neurological deficits as outcome measures for future clinical trials. Investigators will test the hypothesis that worsening gait ataxia and progressive visual loss are caused by ongoing neuronal degeneration. Investigators will develop precise outcome measures based on these deficits to test the efficacy of new treatments. Investigators will prospectively evaluate longitudinal changes in the retinal structure (with optical coherence tomography) and visual function in a cohort of patients with FD. Investigators will determine the extent and severity of retinal abnormalities in all patients and how they change overtime. Investigators will establish whether structural abnormalities in the retina are correlated with disease severity and look for functional correlates as measured by visual acuity and color discrimination. Following the recent discovery that gait ataxia in patients with FD is the result of sensory deficits, investigators will perform quantitative assessments of passive joint angle matching at the knee to measure proprioceptive acuity. Investigators will determine how these measures change overtime as well as their impact on daily function and quality of life.

An organized, multi-site natural history study of patients with FD will enable investigators to define disease-specific outcomes for testing new therapies, a major breakthrough for these patients. The study also offers a unique opportunity to understand better how the brain develops when devoid of crucial sensory inputs.

• Study Type: Observational
• Enrollment (Estimated): 400

Contacts and Locations

• Study Contact: Name: Jose Martinez; Phone Number: 212 263 7225; Email: jose.martinez4@nyulangone.org
• Study Contact Backup: Name: Horacio Kaufmann, MD; Email: horacio.kaufmann@nyulangone.org

Study Locations

• Israel
  • Ramat Gan
    • Tel HaShomer, Ramat Gan, Israel, 52621
      • Recruiting
      • Sheba Medical Center - Safra Children's Hospital
      • Contact: Bat El Bar Aluma, MD; Phone Number: +972 52 666 8335; Email: BatEl.BarAluma@sheba.health.gov.il
      • Contact: Reut Ramon, MPH; Phone Number: +972 52 666 7031; Email: Reut.Ramon@sheba.health.gov.il
• United States
  • New York
    • New York, New York, United States, 10016
      • Recruiting
      • Dysautonomia Center - School of Medicine -NYU Langone Medical Center
      • Principal Investigator: Horacio Kaufmann, MD
      • Contact: Horacio Kaufmann, MD; Email: horacio.kaufmann@nyulangone.org
      • Contact: Jose Martinez; Phone Number: 212-263-7225; Email: jose.martinez4@nyulangone.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 4 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

This study will involve as many as 400 human subjects. Registered patients range from 3 months to 66-years in age. This is a natural history study that will collect information obtained as standard of care from patients with FD.

The study will involve children as it is a genetic disease with onset at birth. Adult patients will also be enrolled.

Description

Inclusion Criteria:

• Patients of any age with a diagnosis of familial dysautonomia (FD) with molecular confirmation of the IKBKAP mutation.
• Ability to provide informed consent (or assent) and comply with the study protocol

Exclusion Criteria:

• Subjects that do not wish to be a part of the study.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Familial Dysautonomia; Patients diagnosed with familial dysautonomia, a genetic disorder that affects the development and survival of nerve cells in the autonomic nervous system. It primarily affects neurons that control involuntary actions like regulation of blood pressure and breathing. It also affects the sensory nervous system and the perception of pain, heat and cold.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
1. To create a database of familial dysautonomia disorder that will serve as a phenotypic core	Investigators will create an enrollment database of patients with familial dysautonomia. All patients will have standardized phenotypic evaluations that will combine clinical, physiological and biochemical strategies to characterize complex autonomic phenotypes, both known and still undiscovered.	5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To define the natural history of visual function and identify predictive biomarkers of disease progression and severity.	Investigators will map the natural history of visual function including retinal structure and visual acuity and test the hypothesis that worsening visual loss is caused by ongoing neuronal degeneration.	5 years
To define the natural history of gait ataxia and identify predictive biomarkers of disease progression and severity	Investigators will map the natural history of gait ataxia and test the hypothesis that progressive ataxia is correlated with increasing loss of proprioceptive acuity caused by ongoing death of sensory neurons.	5 years

Collaborators and Investigators

• Sponsor: NYU Langone Health
• Investigators: Principal Investigator: Horacio Kaufmann, MD, NYU Langone Health

Study record dates

Study Major Dates

• Study Start (Actual): February 22, 2017
• Primary Completion (Estimated): February 21, 2025
• Study Completion (Estimated): December 31, 2025

Study Registration Dates

• First Submitted: April 4, 2019
• First Submitted That Met QC Criteria: April 15, 2019
• First Posted (Actual): April 19, 2019

Study Record Updates

• Last Update Posted (Actual): December 6, 2023
• Last Update Submitted That Met QC Criteria: December 4, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Congenital Abnormalities; Genetic Diseases, Inborn; Neuromuscular Diseases; Neurodegenerative Diseases; Peripheral Nervous System Diseases; Heredodegenerative Disorders, Nervous System; Nervous System Malformations; Polyneuropathies; Nervous System Diseases; Primary Dysautonomias; Autonomic Nervous System Diseases; Hereditary Sensory and Autonomic Neuropathies; Dysautonomia, Familial
• Other Study ID Numbers: 16-01774

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No